Press Releases Nuvalent, Inc.

Equities

NUVL

US6707031075

Real-time Estimate Cboe BZX Other stock markets 12:39:33 2024-06-05 pm EDT			5-day change	1st Jan Change
72.38 ^USD	+2.98%		+9.30%	-1.92%

May. 17	Nuvalent Insider Sold Shares Worth $345,450, According to a Recent SEC Filing	MT
May. 16	Nuvalent Gets FDA Breakthrough Therapy Designation for Lung-Cancer Treatment	DJ

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nuvalent to Participate in the 2024 Jefferies Global Healthcare Conference	May. 29	PR
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results	May. 10	AQ
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results	Feb. 28	AQ
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520	Feb. 28	AQ
Nuvalent to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	Feb. 01	PR
Nuvalent Announces 'OnTarget 2026' Operating Plan and Key Anticipated Milestones	Jan. 09	AQ
Nuvalent to Present at the 42nd Annual J.P. Morgan Healthcare Conference	Dec. 21	PR
Nuvalent Highlights Corporate and Pipeline Achievements and Reports Third Quarter 2023 Financial Results	Nov. 15	AQ
Nuvalent to Participate in the BMO Virtual BioPharma Spotlight Series, Oncology Day	Nov. 02	AQ
Nuvalent to Participate in the BMO Virtual BioPharma Spotlight Series: Oncology Day	Nov. 01	PR
Nuvalent Announces Pricing of Public Offering of Common Stock	23-10-16	PR
Nuvalent Reports Preliminary Phase 1 Clinical Data from ALKOVE-1 Trial that Support Best-In-Class Potential of NVL-655 for Patients with ALK-Positive NSCLC	23-10-16	AQ
Nuvalent Announces Public Offering of Common Stock	23-10-16	PR
Nuvalent, Inc. - Preliminary Phase 1 Dose-Escalation Data from ALKOVE-1 Trial of NVL-655 Demonstrated Activity in Heavily Pre-Treated Patients with ALK-Positive NSCLC and an ALK-Selective, TRK-Sparing Safety Profile	23-10-05	AQ
Nuvalent to Participate in Upcoming September Investor Conferences	23-08-31	PR
Nuvalent Highlights Pipeline Progress and Reports Second Quarter 2023 Financial Results	23-08-11	AQ
Nuvalent to Participate in Upcoming August Investor Conferences	23-08-01	PR
Nuvalent to Participate in the TD Cowen 4th Annual Oncology Innovation Summit	23-05-24	PR
NUVALENT, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)	23-05-11	AQ
Nuvalent to Participate in the Stifel 2023 Virtual Targeted Oncology Days	23-04-19	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Nuvalent, Inc.

Equities

NUVL

US6707031075

Press Releases

Filters